| |
| |
|
| Insider
Information: |
Bentsur Ron |
| Relationship: |
Chairman & CEO, Direct... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
4,184,530 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$50,755 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
4,184,530 |
|
|
| Total
Value |
$50,755 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Keryx Biopharmaceuticals Inc |
KERX |
Chief Executive Office... |
2015-04-06 |
777,209 |
|
0 |
Premium* |
|
|
XTL Biopharmaceuticals Ltd |
XTLBY |
CEO |
2007-08-21 |
20,101 |
|
0 |
Premium* |
|
|
Stemline Therapeutics Inc |
STML |
Director |
2020-06-10 |
0 |
|
0 |
Premium* |
|
|
Beyond Air Ord Shs |
XAIR |
Director |
2023-03-20 |
144,736 |
|
0 |
Premium* |
|
|
Nuvectis Pharma, Inc. |
NVCT |
Chairman & CEO, Direct... |
2024-03-18 |
3,242,484 |
2022-02-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
150 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| KERX |
Keryx Biopharmaceuticals ... |
officerTitle |
• – – |
2003-06-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
13,491 |
|
- |
|
| XTLBY |
XTL Biopharmaceuticals Lt... |
CEOOfficer |
• – – |
2006-08-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,222 |
|
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
CEOOfficer |
• – – |
2009-05-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
206,661 |
|
- |
|
| STML |
Stemline Therapeutics Inc |
Director |
– • – |
2013-01-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,252 |
|
- |
|
| XAIR |
Beyond Air Ord Shs |
Director |
– • – |
2017-03-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
260,079 |
|
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEOOfficer |
• • – |
2022-02-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,565,459 |
|
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-06-22 |
4 |
B |
$13.10 |
$1,310 |
D/D |
100 |
2,963,714 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-07-07 |
4 |
B |
$16.19 |
$1,781 |
D/D |
110 |
3,231,209 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-07-20 |
4 |
B |
$15.06 |
$1,657 |
D/D |
110 |
3,231,669 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-08-16 |
4 |
B |
$15.15 |
$1,742 |
D/D |
115 |
3,232,544 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-06-08 |
4 |
B |
$17.53 |
$2,104 |
D/D |
120 |
3,229,529 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-08-08 |
4 |
B |
$14.83 |
$1,780 |
D/D |
120 |
3,232,014 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-11-25 |
4 |
B |
$7.38 |
$1,107 |
D/D |
150 |
3,015,009 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-11-28 |
4 |
B |
$7.40 |
$1,110 |
D/D |
150 |
3,015,159 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-11-29 |
4 |
B |
$7.45 |
$1,118 |
D/D |
150 |
3,015,309 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-11-30 |
4 |
B |
$7.45 |
$1,118 |
D/D |
150 |
3,015,459 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-07-14 |
4 |
B |
$15.03 |
$2,255 |
D/D |
150 |
3,231,359 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-08-11 |
4 |
B |
$14.66 |
$2,639 |
D/D |
180 |
3,232,194 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-19 |
4 |
B |
$18.95 |
$3,790 |
D/D |
200 |
2,961,614 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-06-23 |
4 |
B |
$11.40 |
$2,280 |
D/D |
200 |
2,963,914 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-05-24 |
4 |
B |
$17.49 |
$3,498 |
D/D |
200 |
3,228,849 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-07-19 |
4 |
B |
$14.33 |
$2,866 |
D/D |
200 |
3,231,559 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-07-21 |
4 |
B |
$14.85 |
$3,341 |
D/D |
225 |
3,231,894 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-03-23 |
4 |
B |
$12.13 |
$2,790 |
D/D |
230 |
3,228,329 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2023-06-07 |
4 |
B |
$17.41 |
$4,004 |
D/D |
230 |
3,229,409 |
3.15 |
- |
|
150 Records found
|
|
Page 1 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
